Comparative Pharmacology
Head-to-head clinical analysis: ANZEMET versus KYTRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANZEMET versus KYTRIL.
ANZEMET vs KYTRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, inhibiting emesis.
Selective serotonin 5-HT3 receptor antagonist, blocking serotonin binding at vagal nerve terminals and central nervous system chemoreceptor trigger zone.
100 mg orally once daily, or 1.8 mg/kg (maximum 100 mg) intravenously over 15 minutes once daily.
2 mg orally once daily or 1 mg intravenously 30 minutes before chemotherapy. For prevention of nausea/vomiting, 2 mg orally 1 hour before chemotherapy or 1 mg IV over 30 seconds.
None Documented
None Documented
The terminal elimination half-life is approximately 5-7 hours in normal adults, but may be prolonged in patients with hepatic impairment (up to 11 hours) or severe renal impairment.
Terminal elimination half-life is 5.9 hours in healthy young adults; in cancer patients, it may be prolonged to 10-12 hours. Clinical context: supports twice-daily dosing for chemotherapy-induced nausea and vomiting (CINV) prophylaxis.
Approximately 70% of the dose is excreted in urine (mostly as metabolites, with less than 10% as unchanged drug) and about 20% in feces via biliary elimination.
Approximately 16% of the dose is excreted unchanged in urine; 44% is eliminated as metabolites (mainly 5-hydroxygranisetron) in urine, and 33% is excreted in feces as metabolites. Renal clearance accounts for about 30% of total clearance.
Category C
Category C
Antiemetic (5-HT3 Antagonist)
Antiemetic (5-HT3 Antagonist)